Rates of corticosteroid treatment after ICI treatment across cancer type, ICI and AID*†
| Oral prednisone | Intravenous methylprednisolone | |||
| AID | No AID | AID | No AID | |
| Melanoma PD-1 inhibitors | 24.0%* (6/25) (RR=2.4) | 9.9% (32/323) | 1.9% (1/54)(RR=1.3) | 1.5% (7/480) |
| Lung cancer PD-1 inhibitors | 14.1% (10/71) (RR=1.7) | 8.3% (104/1250) | 11.0%*** (15/136) (RR=2.6) | 4.3% (74/1711) |
| All cancers PD-1 inhibitors | 16.7%** (16/96) (RR=1.9) | 8.6% (131/1573) | 8.4%** (16/190) (RR=2.3) | 3.7% (81/2191) |
| Melanoma ipilimumab | 10.7% (3/28) (RR=2.14) | 5.0% (16/323) | 2.1% (2/94) (RR=1.6) | 1.3% (14/1039) |
| Melanoma ipilimumab-nivolumab combo | 14.3% (1/7) (RR=1.2) | 11.6% (5/43) | 14.3% (1/7) (RR=2.9) | 4.9% (2/41) |
*Values with * were significantly different at p<0.05 when comparing AID versus non-AID patients within particular subgroups, values with ** were significant at p<0.01, and values with *** were significant at p<0.001.
†The patient populations for prednisone and methylprednisolone are not identical because the separate analyses required distinct inclusion criteria (see Methods).
AID, autoimmune disease; ICI, immune checkpoint inhibitor; RR, relative risk.